日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies

一项开放标签、剂量递增的 FIGHT-101 研究，旨在评估 pemigatinib 联合靶向治疗、化疗或免疫疗法治疗晚期恶性肿瘤患者的疗效。

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103625
Saleh, M; Barve, M; Subbiah, V; Papadopoulos, K P; Morgensztern, D; Mettu, N B; Roychowdhury, S; Spanggaard, I; Veronese, M L; Tian, C; Silverman, I M; Gutierrez, M
肿瘤
肿瘤免疫
免疫/内分泌
发表日期：2024
文献求助 收藏

Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study

度伐利尤单抗联合曲美利尤单抗治疗复发/转移性头颈部鳞状细胞癌的安全性和临床活性：一项多中心 I 期研究

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2024.103646
Algazi, A; Papadopoulos, K P; Tsai, F; Hansen, A R; Angra, N; Das, M; Sheth, S; Siu, L L
细胞生物学
肿瘤
肿瘤免疫
发表日期：2024
文献求助 收藏

A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours

一项针对晚期实体瘤患者的口服泛FGFR抑制剂ARQ 087的I期研究

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2017.330
Papadopoulos, K P; El-Rayes, B F; Tolcher, A W; Patnaik, A; Rasco, D W; Harvey, R D; LoRusso, P M; Sachdev, J C; Abbadessa, G; Savage, R E; Hall, T; Schwartz, B; Wang, Y; Kazakin, J; Shaib, W L
发表日期：2017
文献求助 收藏

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

copanlisib (BAY 80-6946) 是一种静脉注射的泛 I 类磷脂酰肌醇 3-激酶抑制剂，用于治疗晚期实体瘤和非霍奇金淋巴瘤患者，这是首次人体 I 期研究。

期刊:Annals of Oncology
影响因子:65.4
doi:10.1093/annonc/mdw282
Patnaik, A; Appleman, L J; Tolcher, A W; Papadopoulos, K P; Beeram, M; Rasco, D W; Weiss, G J; Sachdev, J C; Chadha, M; Fulk, M; Ejadi, S; Mountz, J M; Lotze, M T; Toledo, F G S; Chu, E; Jeffers, M; Peña, C; Xia, C; Reif, S; Genvresse, I; Ramanathan, R K
信号转导
淋巴瘤
发表日期：2016
文献求助 收藏

Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.

ficlatuzumab 单药治疗或与厄洛替尼联合治疗难治性晚期实体瘤和多发性骨髓瘤的 I 期临床试验

期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/bjc.2014.290
Patnaik A, Weiss G J, Papadopoulos K P, Hofmeister C C, Tibes R, Tolcher A, Isaacs R, Jac J, Han M, Payumo F C, Cotreau M M, Ramanathan R K
肿瘤
骨髓瘤
肿瘤免疫
发表日期：2014
文献求助 收藏